The drug eliminates cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.
The successful completion of the clinical trial allows Kiadis Pharma to prepare for a Phase III clinical study.
Manja Bouman, CEO, Kiadis Pharma, comments: “Reviroc shares its development platform with two other Kiadis Pharma products: ATIR and Rhitol. The results of this trial therefore mark an important milestone in the development of our entire clinical product pipeline.”
In the non-randomized open label study, 25 patients, each of whom had reached end stage non-Hodgkin’s lymphoma, were treated in multiple centers in Canada. The objective of the study was to determine the safety of the Reviroc treatment and its ability to eliminate cancer cells from a contaminated graft. Reviroc-treated grafts all showed excellent engraftment, indicating that the drug does not negatively impact the graft itself.
The Reviroc clinical trial data was evaluated against a historical patient control group from the center for international blood and marrow transplant research (CIBMTR).
The results for Reviroc-treated patients were compared with results from the CIBMTR database for patients who had received an autologous transplant without Reviroc. The outcome of this comparison shows that the Reviroc-treated patient group had an 80% chance of survival at three years post transplantation, while the CIBMTR control group had a 55% chance of survival at three years post transplantation.
Based on these promising data, Kiadis Pharma will prepare for a clinical Phase III study of Reviroc.